Dutch hospitals face the practical strain of moving oesophageal cancer care away from routine surgery
Active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer asks a difficult question of cancer care systems: when a patient has a clinical complete response, how much confidence is enough to justify watchful follow-up instead of immediate resection? In an area where surgery has long been the default after trimodality treatment, the shift toward surveillance is not simply a change in protocol. It requires surgeons, oncologists, radiologists, endoscopists, and nurse practitioners to agree on how residual disease is judged, how uncertainty is communicated, and how closely patients must be monitored if the operation is deferred.
The qualitative study conducted across six Dutch hospitals set out to map the barriers and facilitators to putting that strategy into practice. Its design matters because implementation problems rarely live in a single discipline. They emerge in the handoffs between outpatient review, radiologic interpretation, endoscopic assessment, and surgical decision-making. In this setting, the central operational challenge is not whether active surveillance can be described in theory. It is whether a hospital can build a shared workflow that reliably identifies the right patients and preserves safety once surgery is no longer automatic.
The investigators used semistructured group interviews with a multidisciplinary set of participants, including medical specialists and nurse practitioners. That approach is well suited to a topic in which perception, trust, and local workflow often shape real-world care as much as formal guidelines do. Group interviews can surface disagreement quickly, which is useful when the goal is to understand where a pathway may break down. They can also reveal where different professions are aligned, and where they are still speaking different clinical languages about the same patient.
Implementation depends on more than clinical eligibility
The study was guided by the Consolidated Framework for Implementation Research, a structure designed to organize the forces that help or hinder adoption of a new practice. In this case, that lens is especially apt. Active surveillance after nCRT depends on dependable staging, careful response assessment, and disciplined follow-up. It also depends on institutional readiness: availability of expertise, agreement on who owns surveillance visits, and confidence that nonoperative management will not translate into delayed salvage for patients with occult residual disease.
Across hospitals, those pressures are likely to differ in predictable ways. Larger centers may have more experience coordinating multimodal oesophageal cancer care, while smaller units may encounter more friction when trying to assemble the same surveillance intensity. Some clinicians will be more comfortable with a strategy that avoids the morbidity of esophagectomy in complete responders; others will naturally worry about the consequence of missing microscopic disease. Both instincts are clinically rational. The first protects patients from major surgery they may not need, while the second reflects the genuine risk that response assessment can never be perfectly certain.
One sentence captures the tension at the heart of the study: surveillance only works when uncertainty is managed, not ignored.
The abstract makes clear that the investigators saw value in involving a broad multidisciplinary group. That is not cosmetic detail. Nurse practitioners often anchor longitudinal follow-up, specialist clinicians judge response and recurrence risk, and procedural specialists determine how and when disease reassessment can be performed. If any one of those groups feels excluded from the pathway, adherence becomes fragile. Implementation in this setting is therefore as much about professional buy-in as it is about diagnostic accuracy.
Group dynamics can sharpen insight while blunting dissent
The design also brings a known trade-off. Semistructured group interviews invite discussion and comparison, which can expose shared barriers and reveal local workarounds that would never appear in a questionnaire. At the same time, group dynamics can suppress minority opinions, especially in hierarchies where junior clinicians or non-physician staff may hesitate to challenge established practice. For a topic like active surveillance, that matters because the most important objections are often the quiet ones: uncertainty about who should be followed, anxiety over missed residual disease, or concern that a surveillance schedule may not be realistic outside a research environment.
The six-hospital setting strengthens the relevance of the work because it extends beyond a single institutional culture. Variation across centers is exactly where implementation studies earn their value. A pathway that succeeds in one Dutch hospital may fail in another if access to endoscopy, imaging cadence, multidisciplinary review, or local confidence in the evidence differs. The study’s breadth helps frame active surveillance as a system-level intervention rather than a purely individual clinical choice.
The biological logic behind surveillance is straightforward, even if the operational pathway is not. Neoadjuvant chemoradiotherapy can eradicate all detectable tumor in a subset of patients, and immediate surgery in those cases may expose them to morbidity without clear oncologic gain. Yet response assessment after treatment remains imperfect, and the possibility of residual disease means surveillance must be structured around timely detection of regrowth or persistence. In practice, that turns the follow-up process into the real treatment backbone. If the monitoring system is weak, the strategy itself becomes weak.
The abstract does not provide the full list of barriers and facilitators identified by the interviews, so any attempt to rank them would overstep the evidence available here. What is already visible, however, is the central implementation problem: a less invasive pathway for oesophageal cancer only works when hospitals trust their assessment tools, align their multidisciplinary teams, and accept that a decision not to operate is itself an active clinical choice. The study’s value lies in making those hidden dependencies visible before they are tested in routine care.